Pembrolizumab reaction - Causes, Treatment & When to See a Doctor

```html

What is Pembrolizumab reaction?

Pembrolizumab reaction refers to any unwanted or adverse effect that occurs after a patient receives pembrolizumab, a checkpoint‑inhibitor immunotherapy used primarily for melanoma, non‑small cell lung cancer, head and neck cancer, bladder cancer, and several other malignancies. Pembrolizumab works by blocking the PD‑1 receptor on T‑cells, allowing the immune system to recognize and attack tumor cells. Because it “releases the brakes” on immunity, the drug can sometimes cause the immune system to attack normal tissue, leading to a spectrum of reactions that range from mild skin rash to life‑threatening organ inflammation.

These reactions are collectively called immune‑related adverse events (irAEs). They may appear weeks to months after the first infusion, and the timing can vary widely depending on the organ involved and the patient’s baseline immune status.<sup>1</sup>

Common Causes

Unlike traditional chemotherapy, pembrolizumab’s side‑effects stem from immune activation rather than direct cytotoxic damage. The most frequent culprits include:

• Skin toxicity – maculopapular rash, pruritus, vitiligo‑like depigmentation.
• Gastrointestinal inflammation – colitis, diarrhea, abdominal pain.
• Endocrine dysfunction – hypothyroidism, hyperthyroidism, adrenal insufficiency, pituitary inflammation (hypophysitis).
• Pulmonary toxicity – pneumonitis, dyspnea, cough.
• Hepatic injury – hepatitis, elevated transaminases.
• Renal involvement – interstitial nephritis.
• Neurologic irAEs – peripheral neuropathy, myasthenia gravis‑like syndrome, Guillain‑Barré‑like syndrome.
• Cardiac inflammation – myocarditis, pericarditis.
• Musculoskeletal complaints – arthralgia, myositis.
• Rare systemic syndromes – hemophagocytic lymphohistiocytosis (HLH), vasculitis.

Associated Symptoms

The clinical picture depends on which organ system is affected. Below is a summary of the most common symptom clusters:

Dermatologic

• Itchy or burning rash, often starting on the trunk or extremities.
• Red or purple patches, sometimes with blistering.
• Vitiligo‑like loss of pigment, especially in melanoma patients.

Gastrointestinal

• Watery diarrhea (≥ 3 stools per day) or bloody stools.
• Abdominal cramping, nausea, loss of appetite.

Endocrine

• Fatigue, weight gain/loss, cold intolerance (hypothyroidism).
• Heat intolerance, palpitations, anxiety (hyperthyroidism).
• Headache, visual changes, nausea, low blood pressure (adrenal insufficiency or hypophysitis).

Pulmonary

• Dry cough, shortness of breath, chest tightness.
• Fever or low‑grade chills without infection.

Hepatic

• Right‑upper‑quadrant discomfort.
• Jaundice, dark urine, pale stools.

Renal

• Decreased urine output, swelling in legs or ankles.
• Elevated creatinine on lab testing.

Neurologic & Cardiac

• Muscle weakness, tingling, facial droop.
• Chest pain, palpitations, rapid heart rate.

When to See a Doctor

Because irAEs can progress quickly, patients on pembrolizumab should contact their oncology team or seek urgent care if they notice any of the following:

• New or worsening rash covering > 30 % of the body.
• Diarrhea ≥ 4 stools per day, especially if bloody.
• Persistent fever > 38 °C (100.4 °F) without an obvious infection.
• Shortness of breath, wheezing, or chest pain.
• Sudden weight change, severe fatigue, or dizziness.
• Signs of hormonal imbalance (e.g., palpitations, confusion, severe nausea).
• Swelling of the legs, decreased urine output, or new flank pain.
• Any neurological deficit such as facial weakness, difficulty speaking, or loss of coordination.

Diagnosis

Diagnosing a pembrolizumab reaction involves a systematic evaluation to rule out infection, disease progression, or other drug toxicities.

Step‑by‑step approach

1. Detailed history – timing of symptom onset relative to pembrolizumab dosing, concomitant medications, and prior irAEs.
2. Physical examination – focused exam based on the organ system involved (skin, abdomen, lungs, neurologic exam, etc.).
3. Laboratory tests
   • Complete blood count (CBC) with differential.
   • Liver panel (ALT, AST, bilirubin, alkaline phosphatase).
   • Renal panel (creatinine, BUN, electrolytes).
   • Thyroid function tests (TSH, free T4).
   • Inflammatory markers (CRP, ESR).
4. Imaging – Chest X‑ray or CT for pneumonitis; abdominal CT or MRI for colitis or hepatitis when indicated.
5. Specialized tests
   • Endocrine work‑up: cortisol, ACTH, pituitary MRI if hypophysitis suspected.
   • Stool studies for infectious causes of diarrhea.
   • Neurologic studies: EMG, nerve conduction, or MRI brain/spine for neurological irAEs.
6. Biopsy (rare) – In refractory cases, tissue biopsy (skin, liver, colon) may confirm immune‑mediated inflammation.

Guidelines from the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO) are routinely used to grade irAEs from 1 (mild) to 4 (life‑threatening). This grading determines the treatment algorithm.<sup>2</sup>

Treatment Options

Management depends on severity, the affected organ, and the patient’s overall cancer status.

General principles

• Hold pembrolizumab – Most grade ≥ 2 irAEs require temporary discontinuation.
• Corticosteroids – Prednisone 0.5–1 mg/kg/day (or IV methylprednisolone 1–2 mg/kg/day for severe cases) is first‑line for most irAEs.
• Tapering – Gradual taper over 4‑6 weeks to prevent rebound inflammation.
• Immunosuppressive agents – Mycophenolate, infliximab, or azathioprine for steroid‑refractory disease.
• Re‑challenge – After resolution to grade ≤ 1, many oncologists resume pembrolizumab with close monitoring, especially if the drug provided clinical benefit.

Organ‑specific treatment

Organ System	First‑line	Second‑line (if steroids fail)
Skin (rash, pruritus)	Topical steroids, antihistamines; oral prednisone 0.5 mg/kg for grade ≥ 2	Systemic immunosuppressants (e.g., mycophenolate)
GI (colitis)	IV methylprednisolone 1–2 mg/kg	Infliximab 5 mg/kg (single dose, repeat if needed) or vedolizumab
Endocrine	Hormone replacement (levothyroxine, hydrocortisone) + steroids if inflammation present	High‑dose steroids if pituitary inflammation; endocrine referral
Pulmonary (pneumonitis)	IV methylprednisolone 1–2 mg/kg	Mycophenolate mofetil or cyclophosphamide
Hepatic	Prednisone 1 mg/kg	Mycophenolate or tacrolimus
Renal	Prednisone 1 mg/kg	Azathioprine or mycophenolate
Neurologic	High‑dose IV methylprednisolone 1–2 g/day for 3–5 days	IVIG, plasmapheresis, or rituximab
Cardiac (myocarditis)	High‑dose IV methylprednisolone 1–2 g/day + cardiology input	Infliximab contraindicated; consider mycophenolate, anti‑TNF agents, or abatacept

Home & supportive care

• Maintain adequate hydration, especially with diarrhea.
• Use gentle skin moisturizers and avoid harsh soaps.
• Take antacids or proton‑pump inhibitors if gastritis develops.
• Monitor temperature twice daily while on steroids.
• Keep a symptom diary and report new changes promptly.

Prevention Tips

While irAEs cannot be entirely prevented, several strategies can reduce risk and facilitate early detection:

1. Pre‑treatment assessment – Baseline labs (CBC, liver/renal panel, thyroid studies) and imaging help identify pre‑existing organ dysfunction.
2. Patient education – Explain typical warning signs and provide written instructions on when to call the clinic.
3. Regular monitoring – Labs every 3‑4 weeks for the first 3‑4 months, then every 6‑8 weeks, per ASCO guidelines.<sup>2</sup>
4. Vaccinations – Ensure influenza and COVID‑19 vaccines are up‑to‑date before starting therapy to avoid confounding infections.
5. Avoid concurrent immunosuppressants unless medically required, as they may blunt pembrolizumab efficacy.
6. Prompt treatment of mild irAEs – Early use of topical steroids or low‑dose oral steroids can stop progression to severe disease.
7. Lifestyle measures – Adequate sleep, balanced diet, and stress‑reduction techniques support overall immune regulation.

Emergency Warning Signs

If any of the following occurs, seek emergency care (ER or call 911) immediately. These signs may indicate a life‑threatening irAE:

• Severe shortness of breath, chest pain, or new oxygen requirement.
• Sudden onset of severe headache, vision changes, confusion, or seizures.
• Rapid heart rate (> 120 bpm) with low blood pressure or fainting.
• Persistent high‑grade fever (> 39 °C / 102.2 °F) despite antipyretics.
• Bloody diarrhea (> 3 stools/day) with abdominal cramping.
• Jaundice, dark urine, or sudden swelling of the abdomen.
• Severe muscle weakness that interferes with breathing or swallowing.
• New rash that spreads rapidly, especially with blistering or skin detachment.

---

References:

1. National Cancer Institute. Immune Checkpoint Inhibitor–Related Adverse Events. 2023. cancer.gov.
2. ASCO Clinical Practice Guideline Update: Management of Immune‑Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy. J Clin Oncol. 2022;40(23):2595‑2615. PMID: 35751333.
3. Mayo Clinic. Pembrolizumab (Keytruda) side effects. Updated 2023. mayoclinic.org.
4. World Health Organization. Cancer Immunotherapy. WHO Fact Sheet. 2022.
5. Cleveland Clinic. Immune‑Related Adverse Effects of Checkpoint Inhibitors. 2024. clevelandclinic.org.

```